Hans Jaeger

Inadequate PTH Response to Hypocalcemia in People Living with HIV.

Hans Jaeger, Veronika Schoenitzer, Annamaria Balogh, Eva Wolf

BACKGROUND: Small experimental studies suggest that PTH-secretion following hypocalcemia might be blunted in people living with HIV. OBJECTIVE: The aim of the study was to estimate the frequency of inadequately low concentrations of parathyroid hormone in the presence of hypocalcemia in people …

de, mx (code pays fourni par la source)

HIV and SARS-CoV-2 Coinfection - Cross-Sectional Findings from a German 'Hotspot'

Sebastian Noé, Farhad Schabaz, Silke Heldwein, Wolfgang J. Mayer et autres

de (code pays fourni par la source)

Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study

Miranda Murray, Federico Pulido, Anthony Mills, Moti Ramgopal et autres

Background: Long-acting (LA) injectable antiretroviral therapy (ART) is a novel modality currently under development as an alternative to daily oral ART.Objective: The LATTE-2 study (ClinicalTrials.gov identifier NCT02120352) showed that cabotegravir LA + rilpivirine LA maintained virologic suppression through 96 weeks and included …

gb, es, us, ca, de, be (code pays fourni par la source)

Safety analysis of German real-life cohort WIP shows rates of neuropsychiatric events leading to discontinuation of raltegravir therapy below 2%

Uta Naumann, A Moll, D. Schleehauf, KT Lutz et autres

de (code pays fourni par la source)

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial

Jean‐Michel Molina, Kathleen Squires, Paul E. Sax, Pedro Cahn et autres

fr, us, ar (code pays fourni par la source)

Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial

Pedro Cahn, Richard Kaplan, Paul E. Sax, Kathleen Squires et autres

ar, Afrique du Sud, us, fr, th, au, be (code pays fourni par la source)

Similar efficacy and tolerability of raltegravir-based antiretroviral therapy in HIV-infected patients, irrespective of age group, burden of comorbidities and concomitant medication: Real-life analysis of the German ‘WIP’ cohort

Uta Naumann, A Moll, D. Schleehauf, Thomas A. Lutz et autres

Only limited efficacy and tolerability data on raltegravir (RAL) use are currently available. Study objectives were to describe the efficacy and tolerability profile of RAL-based antiretroviral therapy (ART) in routine clinical practice in Germany. The WIP study (WIP = "Wirksamkeit von Isentress …

de (code pays fourni par la source)

Dolutegravir Monotherapy as Treatment De-Escalation in HIV-Infected Adults with Virological Control: DoluMono Cohort Results

Celia Oldenbuettel, Eva Wolf, Ayla Ritter, Sebastian Noé et autres

BACKGROUND: The potential toxicity of long-term antiretroviral therapy (ART) requires ongoing investigation of novel strategies for treatment of HIV-infected patients. Monotherapy with the integrase inhibitor (INSTI) dolutegravir (DTG) may offer a favourable safety profile. Additionally, DTG has a high barrier of resistance, …

de (code pays fourni par la source)

Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: A randomised placebo-controlled study

Thomas Harrer, Andreas Plettenberg, Keikawus Arastéh, Jan van Lunzen et autres

The human immunodeficiency virus type-1 (HIV-1) vaccine candidate F4/AS01 has previously been shown to induce potent and persistent polyfunctional CD4(+) T-cell responses in HIV-1-seronegative volunteers. This placebo-controlled study evaluated two doses of F4/AS01 1-month apart in antiretroviral treatment (ART)-experienced and ART-naïve HIV-1-infected …

de, be, ch (code pays fourni par la source)

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial

François Raffi, Hans Jaeger, Eugenia Quirós-Roldán, Helmut Albrecht et autres

fr, de, it, us, ru, es, ca (code pays fourni par la source)

Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection

Guenther Schmutz, Mark Nelson, Thomas A. Lutz, Julie Sheldon et autres

OBJECTIVE: At present sequential monotherapy for chronic hepatitis B with hepatitis B virus (HBV)-polymerase inhibitors is clinical practice. It is unknown to date whether combination therapy with lamivudine plus tenofovir could be superior to sequential therapy with tenofovir after the occurrence of …

de, gb, ch, es, it (code pays fourni par la source)

Comparison of Metabolic Abnormalities and Clinical Lipodystrophy 48 Weeks After Switching from HAART to Trizivir™ Versus Continued HAART: The Trizal Study

Alain Lafeuillade, Clumeck Nathan, Josep Mallolas, Hans Jaeger et autres

PURPOSE: To analyze the evolution of clinical lipodystrophy (LD) and metabolic abnormalities in patients continuing to receive HAART versus patients switched to Trizivir (zidovudine, lamivudine, abacavir) after 48 weeks. METHOD: Patients treated with HAART >6 months with plasma HIV-1 RNA viral load …

be, es, de, fr, pt, gb (code pays fourni par la source)